Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-146.34	-143.1	-165.29	-124.09	-196.27	-199.59
Depreciation & Amortization	0.33	0.53	0.62	0.79	0.97	0.97
Share-Based Compensation	21.29	21.71	35.4	29.78	24.41	15.29
Other Operating Activities	7.18	28.14	-20.28	-13.6	10.66	-7.5
Operating Cash Flow	-117.54	-92.72	-149.55	-107.12	-160.23	-190.82
Capital Expenditures	-0.2	0	-0.12	-0.21	-0.15	-0.21
Change in Investments	62.46	7.94	-104.14	147.55	-53.54	78.66
Other Investing Activities	-	-	-	-5.5	-	-
Investing Cash Flow	62.27	7.94	-104.26	141.84	-53.69	78.45
Share Issuance / Repurchase	1.12	1.12	193.74	13.65	172.08	50.7
Debt Issued / Paid	0	0	0	0	0	73.61
Other Financing Activities	-	-	-	60	-	-
Financing Cash Flow	1.12	1.12	193.74	73.65	172.08	124.31
Exchange Rate Effect	-0.01	-0.03	-0.49	-0.05	0.27	0.02
Net Cash Flow	-54.15	-83.69	-60.56	108.32	-41.57	11.95
Free Cash Flow	-117.73	-92.72	-149.67	-107.33	-160.38	-191.03
Free Cash Flow Margin	-83.82%	-63.49%	-95.29%	-51.15%	-148.38%	-467.14%
Free Cash Flow Per Share	-1.02	-0.81	-1.83	-1.43	-2.23	-3.08

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).